GAMP 5 2nd Edition (July 2022) key updates + FDA Computer Software Assurance (CSA) coordination. AI/ML SYSTEMS: dedicated guidance on validation of AI/ML in pharma (predictive maintenance + image analysis + drug discovery + clinical decision support); training + validation + retraining cycles + monitoring + bias detection + explainability + adaptive AI/ML controlled-change management; coordinated with FDA AI/ML Software as a Medical Device (SaMD) Action Plan + EU AI Act + IMDRF AI Working Group. CLOUD COMPUTING + SaaS: shared-responsibility model + supplier qualification + business continuity + data sovereignty + multi-tenant considerations + IaaS/PaaS/SaaS lifecycle differences; integrates with FedRAMP-like sector certifications + ISO 27001/27017/27018 + ISPE cloud guidance. AGILE + ITERATIVE DEVELOPMENT: scrum/kanban/SAFe adaptation; sprint-level documentation + risk assessment + acceptance criteria + lifecycle artifacts in sprint outputs; balance regulatory compliance with iterative speed. DEVOPS + CI/CD: automated testing + deployment pipelines + version control + infrastructure-as-code + automated validation; emphasis on test automation reducing manual qualification effort. FDA COMPUTER SOFTWARE ASSURANCE (CSA) - 2022 Draft Guidance: risk-based + critical-thinking-driven + assurance-by-assessment + reducing reliance on prescriptive testing for low-risk systems; coordinated with GAMP 5 critical-thinking emphasis. CRITICAL THINKING EMPHASIS: throughout 2nd Edition + replacing some prescriptive testing requirements with judgment-based assurance.
This control maps to 53 controls across 28 other frameworks. If you already hold one of them, the evidence you collected for it is the starting point here rather than new work.
Every mapping shown was judged rather than inferred from wording similarity, and the ones that failed review are published too. See the coverage reports and what was rejected.
The graph holds this control, the 53 it maps to, and the evidence behind each claim, over MCP and REST.